XTX301 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

358

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

XTX301

XTX301 monotherapy

Trial Locations (11)

15232

RECRUITING

University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh

43221

RECRUITING

The Ohio State University Wexner Medical Center, Columbus

44106

RECRUITING

University Hospital Cleveland Medical Center, Cleveland

44718

RECRUITING

The Gabrail Pharmacology Phase 1 Research Center, Canton

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

55426

RECRUITING

HealthPartners Frauenshuh Cancer center, Saint Louis Park

63110

RECRUITING

Washington University School of Medicine, St Louis

77598

RECRUITING

Tranquil Clinical Research, Webster

95817

RECRUITING

University of California, Davis Comprehensive Cancer Center, Sacramento

06510

RECRUITING

Yale Cancer Center, New Haven

07601

RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Xilio Development, Inc.

INDUSTRY